Navigation Links
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Date:6/12/2008

- APD125 Significantly Improved Key PSG Parameters of Sleep Maintenance -

- Phase 2b Subjective Study Ongoing -

SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia in an oral presentation at the SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies in Baltimore, Maryland.

APD125 is an oral drug candidate discovered by Arena that is being evaluated for the treatment of insomnia in patients who have difficulty maintaining sleep after initial sleep onset. When compared to placebo in the Phase 2a clinical trial, patients treated with APD125 experienced statistically significant improvements in polysomnographic (PSG) measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep. These improvements were achieved without any next day impairment of cognition or coordination.

"APD125 is a potential next generation treatment for improving sleep maintenance that could meet the needs of many patients looking to achieve better 'quality sleep'," stated Dr. Thomas Roth of Henry Ford Hospital, who interpreted the PSG data for the Phase 2a trial. "In the trial, APD125 clearly demonstrated robust sleep maintenance properties without any apparent pattern of side effects associated with the drug."

Arena is currently evaluating the effects of APD125 on patients' subjective assessment of sleep in a Phase 2b study.

APD125 Phase 2a Study Results

In a Phase 2a clinical trial, APD125 significantly improved several PSG endpoints measuring improve
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
4. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
5. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
... , Jan. 28 , Net Sales of $1.11 ... period (an increase of 2.5% constant currency) , Diluted ... from the prior year period, and $1.12 adjusted, an increase of 12.0% ... of $4.10 billion for the full year represent a decrease of 0.6% ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Zimmer Reports Fourth Quarter and 2009 Financial Results 2Zimmer Reports Fourth Quarter and 2009 Financial Results 3Zimmer Reports Fourth Quarter and 2009 Financial Results 4Zimmer Reports Fourth Quarter and 2009 Financial Results 5Zimmer Reports Fourth Quarter and 2009 Financial Results 6Zimmer Reports Fourth Quarter and 2009 Financial Results 7Zimmer Reports Fourth Quarter and 2009 Financial Results 8Zimmer Reports Fourth Quarter and 2009 Financial Results 9Zimmer Reports Fourth Quarter and 2009 Financial Results 10Zimmer Reports Fourth Quarter and 2009 Financial Results 11Zimmer Reports Fourth Quarter and 2009 Financial Results 12Zimmer Reports Fourth Quarter and 2009 Financial Results 13Zimmer Reports Fourth Quarter and 2009 Financial Results 14Zimmer Reports Fourth Quarter and 2009 Financial Results 15Zimmer Reports Fourth Quarter and 2009 Financial Results 16Zimmer Reports Fourth Quarter and 2009 Financial Results 17Zimmer Reports Fourth Quarter and 2009 Financial Results 18Zimmer Reports Fourth Quarter and 2009 Financial Results 19Zimmer Reports Fourth Quarter and 2009 Financial Results 20Zimmer Reports Fourth Quarter and 2009 Financial Results 21Zimmer Reports Fourth Quarter and 2009 Financial Results 22Zimmer Reports Fourth Quarter and 2009 Financial Results 23Zimmer Reports Fourth Quarter and 2009 Financial Results 24Zimmer Reports Fourth Quarter and 2009 Financial Results 25Zimmer Reports Fourth Quarter and 2009 Financial Results 26Zimmer Reports Fourth Quarter and 2009 Financial Results 27
(Date:7/13/2014)... According to a new market research report "Heterogeneous ... GPU, DSP, connectivity), Technology Node (45nm-5nm), Application (Consumer, ... and Analysis to 2014-2020", published by MarketsandMarkets, the ... expected to reach $61.70 Billion by 2020, growing ... 2020. , Browse 71 market data Tables with ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... as a surprise to politicians and rights leaders alike, mainly ... of girls in the 0-6 years category is coming down ... feticide and nothing else. The problem is that we are ... the guilty," said Health Minister P.K. Sreemathy Thursday while speaking ...
... Southwestern Medical Center, working with mice, have shown how ... decrease the fearful response associated with reliving a traumatic ... a mild electrical shock – mice in the study ... place where it happened, a condition that could be ...
... found a breakthrough in the treatment of breast cancer ... therapies.// ,According to Professor Miles Prince from Melbourne's ... emission tomography (PET) would probably change the way breast ... (PET) scans to monitor breast cancer patients to find ...
... in UK, 40% Of Adults Cannot Manage Without Cell ... Stoke-on-Trent, who had conducted the research//, claimed that certain ... their cell phones. In his study on how students ... of the behaviors displayed, closely resembled symptoms of ‘pathological ...
... Richards marks the rapid increase in esophageal cancer cases in the ... cancer.// Only 16 % or around 2,200, of the 14,000-esophageal cancer ... years. ,There has been a 6-fold annual rise in the ... to experts. Rise in obesity cases has been the major cause. ...
... can be effective in cluster headaches as well, researchers ... pain signals, Dr. Peter Goadsby, professor of clinical neurology ... not as common as migraines and affect one in ... In the final analysis 69 patients were included. These ...
Cached Medicine News:Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 2Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 3Health News:Aussie Doctors Claim Breakthrough in Breast Cancer Treatment 2Health News:Rise in Esophageal Cancer is emphasized by Richards’ deat 2
Microsect Curette with increased cutting edge and modified shaft, 10"....
Bone Curette, 160 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: